In the near future, we believe that hydrogen rooms will be installed in individual homes to treat both pre-symptomatic and symptomatic diseases, as well as to prevent aging.
MiZ Inc. has been involved in promoting the research and development of the widespread use of molecular hydrogen with the hopes that it will propel the next generation of medical care.
Molecular hydrogen is an inert substance that does not react in the human body. Of the reactive oxygen species within our bodies, only hydroxyl radicals, which have the strongest oxidizing power, can oxidize these inert hydrogen molecules. During this oxidation reaction, hydrogen molecules scavenge hydroxyl radicals and convert them into water. In such a way, inert hydrogen molecules can be regarded as selective radical scavengers of hydroxyl radicals, and this property of hydrogen has been overlooked in conventional medicine.
Hydroxyl radicals are mainly generated in the mitochondria. Only hydrogen molecules, which are the smallest dimeric molecules in the human body, can directly scavenge hydroxyl radicals within the mitochondria to prevent, improve, and resolve symptoms of diseases by suppressing oxidative stress and chronic inflammation. Thus, we believe that hydrogen-producing bacteria, such as Bacteroides and Firmicutes, are more beneficial to human health than other intestinal bacteria, as they are the main sources of hydrogen in the body.
Hydrogen molecules ameliorate chronic diseases by suppressing oxidative stress and chronic inflammation, but unlike conventional medicine, they do not target specific diseases. Hydrogen molecules spread throughout the body in the bloodstream and suppress chronic inflammation locally in the locations where they are delivered, thereby treating chronic diseases. More specifically, if chronic inflammation in a specific location of the body was causing ulcerative colitis, the hydrogen would treat the ulcerative colitis in that location, whereas if chronic inflammation in another location was causing COPD, the hydrogen would treat the COPD in this other location. In addition, given the small size of the molecule, hydrogen gas can penetrate the blood-brain barrier to reach the brain directly from the nasal mucosa. As such, inhaling hydrogen gas is particularly effective for brain-related diseases.
We refer to such properties of hydrogen medicine as multi-targeted therapy, in contrast to the single-targeted therapy displayed by traditional pharmaceuticals. While we believe that this type of therapy can be effective for numerous diseases, some people may claim that it is unscientific. However, hydrogen molecules are multi-targeted medical substances by nature. In other words, if a patient has both ulcerative colitis and COPD, it is impossible for hydrogen to treat the ulcerative colitis without doing the same for COPD. As a typical example, past clinical studies have demonstrated cases in which the inhalation of hydrogen gas for the treatment of chronic kidney disease also unintentionally cured the same patient’s diabetes.
In the future, we presume that hydrogen rooms may be installed in individual homes to treat pre-symptomatic and symptomatic diseases, as well as to prevent aging.
MiZ Inc. has been granted exclusive rights to licenses in the United States for all patents related to the medical use of hydrogen, owned by MiZ Company Limited in Japan.
MiZ Inc. seeks to work with companies that wish to commercialize and obtain a license (sublicense) related to the medical use of hydrogen from MiZ Inc., by having these companies hold some of MiZ Inc.’s shares and jointly promote clinical development for target diseases.
For applications that do not require clinical development, such as the treatment of pre-symptomatic diseases, we will promptly commercialize safe and secure hydrogen gas devices, such as hydrogen gas inhalers and chambers, with our partner companies.
We realize that conventional pharmaceutical and medical device companies may be unwilling to accept our proposals because, in a sense, hydrogen medicine negates conventional medicine.
We refer to hydrogen medicine as a multi-targeted therapy, in contrast to the single-targeted therapy displayed by traditional pharmaceuticals. While we believe that this type of therapy can be effective for numerous diseases, some people may claim that it is unscientific. However, we know that hydrogen molecules are multi-targeted medical substances by nature.
If a patient has both ulcerative colitis and COPD, it is impossible for hydrogen to treat the ulcerative colitis without doing the same for COPD. As a typical example, past clinical studies have demonstrated cases in which the inhalation of hydrogen gas for the treatment of chronic kidney disease also unintentionally cured the same patient’s diabetes.
We would like to build partnerships with ambitious companies that are seeking to propel the next generation of medical care in the healthcare industry with novel approaches, regardless of the conventional beliefs about health and illnesses.
| Company name | MiZ Inc. |
| EIN | 86-2542579 |
| Incorporated | Feb 26, 2021 |
| Capital | $ 100,000 |
| CEO | Bunpei Sato |
| COO | Yusuke Ichikawa |
| Location | 39899 Balentine Drive, Suite 200, Newark, California, 94560, USA |
| Phone number | 1-510-933-8376 |
| Principal business | Development and licensing of the medical applications of molecular hydrogen |